Publications by authors named "Zhengzheng Ji"
Background: The risk of immune-related colitis (IRC) and efficacy of immune checkpoint inhibitors (ICIs) in patients with gastrointestinal cancers and preexisting ulcerative colitis (UC) has not been well described.
Patients And Methods: We divided the patients with gastrointestinal cancers and preexisting UC who received ICIs between January 2021 and May 2024 into two groups as IRC group and non-IRC group. The electronic medical records were reviewed to compare the risk of IRC between two groups.
Background: Cancer patients are at a greater risk of experiencing emotional distress (ED) compared to individuals without cancer, with those diagnosed with gastric cancer (GC) exhibiting a higher prevalence of ED than patients with other types of malignancies. A meta-analysis showed that 37% of global GC patients had depressive symptoms. Numerous studies have demonstrated that ED can lead cancer patients to develop immunosuppressive tumor microenvironments (TME), thereby impairing the exertion of antitumor immune effects.
View Article and Find Full Text PDFArticle Synopsis
- * A meta-analysis of 55 studies involving 7,180 HCC patients indicated that HBV infection did not significantly affect overall survival (OS) or progression-free survival (PFS) with ICIs, but HBV-infected patients may have a better tumor response.
- * High baseline HBV load is linked to worse survival outcomes, while antiviral therapy demonstrates improved prognostic outcomes for HCC patients treated with ICIs.
Article Synopsis
- Immune Checkpoint Inhibitors (ICIs) have transformed cancer treatment but can cause immune-related adverse events (irAEs), including pulmonary arterial hypertension (PAH).
- A male patient with intrahepatic cholangiocarcinoma and ankylosing spondylitis developed PAH after undergoing combined ICI therapy, showing fluctuating pulmonary artery pressures (PAP) during and after treatment.
- The patient was successfully treated with a combination of adalimumab, glucocorticoids, and immunosuppressants, indicating that DMARDs may help manage refractory PAH linked to irAEs.
Background: Immune checkpoint inhibitors (ICIs) combined with chemotherapy have been widely employed to improve the outcome of gastric cancer patients. In the present study, the impact of posttreatment growth hormone (GH) levels on the treatment efficacy of ICIs for advanced gastric cancer (AGC) patients was assessed.
Methods: Seventy-five AGC patients treated with anti-PD-1 antibodies at The Fourth Hospital of Hebei Medical University were involved.
Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients.
J Cancer Res Clin Oncol
July 2023
Purpose: Immune checkpoint inhibitors (ICIs) have improved the prognosis of cancer patients significantly with few predictive makers for treatment efficiency. Since interferon-gamma (IFN-γ) displayed its association with immunotherapy, we explored the correlation between IFN-γ and the efficacy of ICIs in tumor treatment.
Methods: We retrospectively examined cancer patients who received immune checkpoint inhibitors as first-line therapy at the Fourth Hospital of Hebei Medical University.